메뉴 건너뛰기




Volumn 61, Issue 11, 2012, Pages 1905-1916

Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells

Author keywords

ADCC; Adenovirus; Extracellular domain; HER2; Trastuzumab

Indexed keywords

ADENOVIRUS VECTOR; PLASMID VECTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR RECEPTOR 2 EXTRACELLULAR DOMAIN; RECOMBINANT PROTEIN; REPLICATION DEFICIENT ADENOVIRUS VECTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

EID: 84870985606     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1249-x     Document Type: Article
Times cited : (25)

References (46)
  • 3
    • 0037099532 scopus 로고    scopus 로고
    • Herceptin-induced inhibition of phosphatidylinositol-3 kinase and akt is required for antibody-mediated evects on p27, cyclin d1, and antitumor action
    • Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated eVects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132-4141
    • (2002) Cancer Res , vol.62 , pp. 4132-4141
    • Yakes, F.M.1    Chinratanalab, W.2    Ritter, C.A.3    King, W.4    Seelig, S.5    Arteaga, C.L.6
  • 5
    • 0032885461 scopus 로고    scopus 로고
    • Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against lfa-3 and her2/neu
    • Cooley S, Burns LJ, Repka T, Miller JS (1999) Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27:1533-1541
    • (1999) Exp Hematol , vol.27 , pp. 1533-1541
    • Cooley, S.1    Burns, L.J.2    Repka, T.3    Miller, J.S.4
  • 6
    • 0034076307 scopus 로고    scopus 로고
    • Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets
    • Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446
    • (2000) Nat Med , vol.6 , pp. 443-446
    • Clynes, R.A.1    Towers, T.L.2    Presta, L.G.3    Ravetch, J.V.4
  • 9
    • 0032850677 scopus 로고    scopus 로고
    • Multinational study of the eycacy and safety of humanized anti-her2 monoclonal antibody in women who have her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    • Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the eYcacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648
    • (1999) J Clin Oncol , vol.17 , pp. 2639-2648
    • Cobleigh, M.A.1    Vogel, C.L.2    Tripathy, D.3    Robert, N.J.4    Scholl, S.5    Fehrenbacher, L.6    Wolter, J.M.7    Paton, V.8    Shak, S.9    Lieberman, G.10    Slamon, D.J.11
  • 12
    • 50849123421 scopus 로고    scopus 로고
    • Her2 in gastric cancer: A new prognostic factor and a novel therapeutic target
    • Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
    • (2008) Ann Oncol , vol.19 , pp. 1523-1529
    • Gravalos, C.1    Jimeno, A.2
  • 15
    • 73349085919 scopus 로고    scopus 로고
    • Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
    • Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27:5838-5847
    • (2009) J Clin Oncol , vol.27 , pp. 5838-5847
    • Spector, N.L.1    Blackwell, K.L.2
  • 18
    • 33846552656 scopus 로고    scopus 로고
    • Escape from her-family tyrosine kinase inhibitor therapy by the kinase-inactive her3
    • Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441
    • (2007) Nature , vol.445 , pp. 437-441
    • Sergina, N.V.1    Rausch, M.2    Wang, D.3    Blair, J.4    Hann, B.5    Shokat, K.M.6    Moasser, M.M.7
  • 19
    • 0346154748 scopus 로고    scopus 로고
    • Molecular mechanisms underlying igf-i-induced attenuation of the growth-inhibitory activity of trastuzumab (herceptin) on skbr3 breast cancer cells
    • Lu Y, Zi X, Pollak M (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108:334-341
    • (2004) Int J Cancer , vol.108 , pp. 334-341
    • Lu, Y.1    Zi, X.2    Pollak, M.3
  • 20
    • 28244432561 scopus 로고    scopus 로고
    • Insulin-like growth factor-i receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
    • Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128
    • (2005) Cancer Res , vol.65 , pp. 11118-11128
    • Nahta, R.1    Yuan, L.X.2    Zhang, B.3    Kobayashi, R.4    Esteva, F.J.5
  • 22
    • 0034920457 scopus 로고    scopus 로고
    • Loss of expression of the pten gene protein product is associated with poor outcome in breast cancer
    • Depowski PL, Rosenthal SI, Ross JS (2001) Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14:672-676
    • (2001) Mod Pathol , vol.14 , pp. 672-676
    • Depowski, P.L.1    Rosenthal, S.I.2    Ross, J.S.3
  • 23
    • 9244219598 scopus 로고    scopus 로고
    • Breast cancer -loss of pten predicts resistance to treatment
    • PandolW PP (2004) Breast cancer -loss of PTEN predicts resistance to treatment. N Engl J Med 351:2337-2338
    • (2004) N Engl J Med , vol.351 , pp. 2337-2338
    • PandolW, P.P.1
  • 25
    • 77953678688 scopus 로고    scopus 로고
    • Understanding and circumventing resistance to anticancer monoclonal antibodies
    • Reslan L, Dalle S, Dumontet C (2009) Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 1:222-229
    • (2009) MAbs , vol.1 , pp. 222-229
    • Reslan, L.1    Dalle, S.2    Dumontet, C.3
  • 26
    • 18344390418 scopus 로고    scopus 로고
    • Erbb receptors and cancer: The complexity of targeted inhibitors
    • Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
    • (2005) Nat Rev Cancer , vol.5 , pp. 341-354
    • Hynes, N.E.1    Lane, H.A.2
  • 28
    • 0029162564 scopus 로고
    • Heregulin-dependent regulation of her2/neu oncogenic signaling by heterodimerization with her3
    • Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A (1995) Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14:4267-4275
    • (1995) EMBO J , vol.14 , pp. 4267-4275
    • Wallasch, C.1    Weiss, F.U.2    Niederfellner, G.3    Jallal, B.4    Issing, W.5    Ullrich, A.6
  • 31
    • 1642422374 scopus 로고    scopus 로고
    • Association with membrane protrusions makes erbb2 an internalization- resistant receptor
    • Hommelgaard AM, Lerdrup M, van Deurs B (2004) Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15:1557-1567
    • (2004) Mol Biol Cell , vol.15 , pp. 1557-1567
    • Hommelgaard, A.M.1    Lerdrup, M.2    Van Deurs, B.3
  • 32
    • 27244450053 scopus 로고    scopus 로고
    • Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma
    • Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, Fujii H (2005) Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11:4898-4904
    • (2005) Clin Cancer Res , vol.11 , pp. 4898-4904
    • Mimura, K.1    Kono, K.2    Hanawa, M.3    Kanzaki, M.4    Nakao, A.5    Ooi, A.6    Fujii, H.7
  • 33
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with ampliwcation of the her-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with ampliWcation of the HER-2/neu oncogene. Science 235:177-182
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3    Levin, W.J.4    Ullrich, A.5    McGuire, W.L.6
  • 34
    • 0023857935 scopus 로고
    • Correlation of c-erbb-2 gene ampliwcation and protein expression in human breast carcinoma with nodal status and nuclear grading
    • Berger MS, Locher GW, Saurer S, Gullick WJ, WaterWeld MD, Groner B, Hynes NE (1988) Correlation of c-erbB-2 gene ampliWcation and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243
    • (1988) Cancer Res , vol.48 , pp. 1238-1243
    • Berger, M.S.1    Locher, G.W.2    Saurer, S.3    Gullick, W.J.4    WaterWeld, M.D.5    Groner, B.6    Hynes, N.E.7
  • 37
    • 0037142184 scopus 로고    scopus 로고
    • Rat muc4 (sialomucin complex) reduces binding of anti-erbb2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance
    • Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99:783-791
    • (2002) Int J Cancer , vol.99 , pp. 783-791
    • Price-Schiavi, S.A.1    Jepson, S.2    Li, P.3    Arango, M.4    Rudland, P.S.5    Yee, L.6    Carraway, K.L.7
  • 38
    • 12544250996 scopus 로고    scopus 로고
    • Decreased accessibility and lack of activation of erbb2 in jimt-1, a herceptin-resistant, muc4-expressing breast cancer cell line
    • Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473-482
    • (2005) Cancer Res , vol.65 , pp. 473-482
    • Nagy, P.1    Friedlander, E.2    Tanner, M.3    Kapanen, A.I.4    Carraway, K.L.5    Isola, J.6    Jovin, T.M.7
  • 40
    • 3042521542 scopus 로고    scopus 로고
    • Cellular dynamics visualized in live cells in vitro and in vivo by diverential dual-color nuclear-cytoplasmic xuorescent-protein expression
    • Yamamoto N, Jiang P, Yang M, Xu M, Yamauchi K, Tsuchiya H, Tomita K, Wahl GM, Moossa AR, HoVman RM (2004) Cellular dynamics visualized in live cells in vitro and in vivo by diVerential dual-color nuclear-cytoplasmic Xuorescent-protein expression. Cancer Res 64:4251-4256
    • (2004) Cancer Res , vol.64 , pp. 4251-4256
    • Yamamoto, N.1    Jiang, P.2    Yang, M.3    Xu, M.4    Yamauchi, K.5    Tsuchiya, H.6    Tomita, K.7    Wahl, G.M.8    Moossa, A.R.9    HoVman, R.M.10
  • 41
    • 25844461626 scopus 로고    scopus 로고
    • The multiple uses of xuorescent proteins to visualize cancer in vivo
    • HoVman RM (2005) The multiple uses of Xuorescent proteins to visualize cancer in vivo. Nat Rev Cancer 5:796-806
    • (2005) Nat Rev Cancer , vol.5 , pp. 796-806
    • HoVman, R.M.1
  • 42
    • 0030844812 scopus 로고    scopus 로고
    • Suppressed cellmediated immunity and monocyte and natural killer cell activity following allogeneic immunization of women with spontaneous recurrent abortion
    • Gafter U, Sredni B, Segal J, Kalechman Y (1997) Suppressed cellmediated immunity and monocyte and natural killer cell activity following allogeneic immunization of women with spontaneous recurrent abortion. J Clin Immunol 17:408-419
    • (1997) J Clin Immunol , vol.17 , pp. 408-419
    • Gafter, U.1    Sredni, B.2    Segal, J.3    Kalechman, Y.4
  • 43
    • 0037108686 scopus 로고    scopus 로고
    • Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer
    • Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62:5813-5817
    • (2002) Cancer Res , vol.62 , pp. 5813-5817
    • Kono, K.1    Takahashi, A.2    Ichihara, F.3    Sugai, H.4    Fujii, H.5    Matsumoto, Y.6
  • 44
    • 1642566826 scopus 로고    scopus 로고
    • Tumor-inwltrating lymphocyte secretion of il-6 antagonizes tumor-derived tgfbeta 1 and restores the lymphokine-Activated killing activity
    • Hsiao YW, Liao KW, Hung SW, Chu RM (2004) Tumor-inWltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGFbeta 1 and restores the lymphokine-Activated killing activity. J Immunol 172:1508-1514
    • (2004) J Immunol , vol.172 , pp. 1508-1514
    • Hsiao, Y.W.1    Liao, K.W.2    Hung, S.W.3    Chu, R.M.4
  • 45
    • 0028116922 scopus 로고
    • The lack of nk cytotoxicity associated with fresh hucb may be due to the presence of soluble hla in the serum
    • Webb BJ, Bochan MR, Montel A, Padilla LM, Brahmi Z (1994) The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum. Cell Immunol 159:246-261
    • (1994) Cell Immunol , vol.159 , pp. 246-261
    • Webb, B.J.1    Bochan, M.R.2    Montel, A.3    Padilla, L.M.4    Brahmi, Z.5
  • 46
    • 0033367649 scopus 로고    scopus 로고
    • Interleukin-10 reduces natural killer (nk) sensitivity of tumor cells by downregulating nk target structure expression
    • Tsuruma T, Yagihashi A, Hirata K, Torigoe T, Araya J, Watanabe N, Sato N (1999) Interleukin-10 reduces natural killer (NK) sensitivity of tumor cells by downregulating NK target structure expression. Cell Immunol 198:103-110
    • (1999) Cell Immunol , vol.198 , pp. 103-110
    • Tsuruma, T.1    Yagihashi, A.2    Hirata, K.3    Torigoe, T.4    Araya, J.5    Watanabe, N.6    Sato, N.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.